Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85])
Regenerons Strategy in the Obesity Market Regeneron Pharmaceuticals licensed olatorepatide from Jiangsu Hansoh Pharmaceutical Group Co., Ltd
GIP looks a lot like GLP-1, so rather than administer two drugs, researchers created one peptide that incorporates structural elements of both -- what's called in drug development a chimera
[DOI] [PubMed] [Google Scholar] Chang X
van der Lugt et al., 2019), this may be due to the increased goblet cell count and reduced crypt depth